spark therapeutics inc developer gene therapy treatments treat debilitating genetic subsidiary hoffmannla roche company founded katherine high jeffrey marrazzo steven effort commercially develop treatments haemophilia high working childrens hospital january company became public company trading ticker via million initial public led chief legal officer joseph la december us food drug administration approved luxturna voretigene neparvovecrzyl treatment patients viable retinal cells confirmed biallelic mutationassociated retinal dystrophy genetic blinding condition caused mutations company currently developing several gene therapies target suite diseases including haemophilia b several central nervous system diseases december company acquired hoffmannla roche continues operate independent subsidiary since acquisition swiss pharma roche several key founding executives departed including scientist cofounder katherine high february chief businesslegal officer joseph la barge december cofounder chief executive officer jeffrey marrazzo april february marrazzo named bigpharma veteran ron philip successor mr philip currently leads company gene therapy product candidates clinical development candidate spkfviii program hemophilia ii product candidate hemophilia inhibitor market iii targeting choroideremia chm lead product candidate spkfix program hemophilia b developed partnership voretigene neparvovec marketed tradename luxturna gene therapy approved food drug administration treatment lebers congenital amaurosis rare genetic eye fidanacogene elaparvovec previously known study id number experimental drug investigation treatment hemophilia b partnership pfizer fidanacogene elaparvovec adenoassociated viral vector designed transfer working copy factor ix gene livers patients carry nonfunctioning july fidanacogene elaparvovec entered late stage clinical experimental drug investigation treatment haemophilia entering phase iii clinical trials united states therapy transfers working copy factor viii gene patients lack one phase ii clinical trials patients receiving highest dose drug suffered immune responses one patient hospitalized reactions treatment seen setback though spark suggested responses could controlled steroids promised move forward phase iii experimental drug investigation treatment choroideremia genetic disorder causes experimental drug investigation treatment pompe disease genetic disorder leads failure correctly metabolize experimental drug investigation treatment batten disease fatal genetic nervous system httpsenwikipediaorgwikisparktherapeutics